Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Dec 10

PMID 34885113

Citations 5

Authors

Lucy Hare

G A Amos Burke

Suzanne D Turner

Affiliations

Soon will be listed here.

Abstract

Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.

Citing Articles

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma.

Gleason L, Afifi L, Banner L, Talasila S, Joffe D, Bhatti S Mol Clin Oncol. 2024; 20(5):35.

PMID: 38596625 PMC: 11002836. DOI: 10.3892/mco.2024.2733.

Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.

Bisig B, Savage K, de Leval L Haematologica. 2023; 108(12):3227-3243.

PMID: 38037800 PMC: 10690915. DOI: 10.3324/haematol.2023.282716.

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.

Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-Hara T, Uchibori K JCI Insight. 2023; 8(24).

PMID: 37917191 PMC: 10807714. DOI: 10.1172/jci.insight.173688.

Genomic profiling for clinical decision making in lymphoid neoplasms.

de Leval L, Alizadeh A, Bergsagel P, Campo E, Davies A, Dogan A Blood. 2022; 140(21):2193-2227.

PMID: 36001803 PMC: 9837456. DOI: 10.1182/blood.2022015854.

The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.

Derebas J, Panuciak K, Margas M, Zawitkowska J, Lejman M Cancers (Basel). 2022; 14(6).

PMID: 35326719 PMC: 8945992. DOI: 10.3390/cancers14061569.

References

Bai R, Dieter P, Peschel C, Morris S, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61. PMC: 109278. DOI: 10.1128/MCB.18.12.6951. View

Gambacorti-Passerini C, Mussolin L, Brugieres L . Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016; 374(1):95-6. DOI: 10.1056/NEJMc1511045. View

De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F . Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers (Basel). 2021; 13(9). PMC: 8122870. DOI: 10.3390/cancers13092040. View

Huber R, Hansen K, Paz-Ares Rodriguez L, West H, Reckamp K, Leighl N . Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2019; 15(3):404-415. DOI: 10.1016/j.jtho.2019.11.004. View

Ross-Macdonald P, Walsh A, Chasalow S, Ammar R, Papillon-Cavanagh S, Szabo P . Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021; 9(3). PMC: 7931766. DOI: 10.1136/jitc-2020-001506. View

Gristina V, La Mantia M, Iacono F, Galvano A, Russo A, Bazan V . The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7766858. DOI: 10.3390/ph13120474. View

Kim Y, Vagia E, Viveiros P, Kang C, Lee J, Gim G . Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). Cancer Immunol Immunother. 2020; 70(4):961-965. PMC: 10991863. DOI: 10.1007/s00262-020-02703-8. View

Roskoski Jr R . Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res. 2017; 117:343-356. DOI: 10.1016/j.phrs.2017.01.007. View

Strauss L, Mahmoud M, Weaver J, Tijaro-Ovalle N, Christofides A, Wang Q . Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020; 5(43). PMC: 7183328. DOI: 10.1126/sciimmunol.aay1863. View

10.

Dong X, Fernandez-Salas E, Li E, Wang S . Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia. 2016; 18(3):162-71. PMC: 4796802. DOI: 10.1016/j.neo.2016.02.001. View

11.

Meng Z, Li T, Wang P, Lizaso A, Huang D . The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. Cancer Biol Ther. 2020; 22(1):1-4. PMC: 7834046. DOI: 10.1080/15384047.2020.1836947. View

12.

Ai X, Niu X, Chang L, Chen R, Ou S, Lu S . Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. Lung Cancer. 2018; 123:83-86. DOI: 10.1016/j.lungcan.2018.07.004. View

13.

Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H . Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020; 10(3):1033-1045. PMC: 6956820. DOI: 10.7150/thno.38137. View

14.

Gao L, Wu Z, Assaraf Y, Chen Z, Wang L . Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021; 57:100770. DOI: 10.1016/j.drup.2021.100770. View

15.

Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik M . Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A. 2006; 103(26):9964-9. PMC: 1502562. DOI: 10.1073/pnas.0603507103. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Brugieres L, Le Deley M, Rosolen A, Williams D, Horibe K, Wrobel G . Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009; 27(6):897-903. DOI: 10.1200/JCO.2008.18.1487. View

18.

McCoy M, Madhavan S . A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase. AMIA Jt Summits Transl Sci Proc. 2018; 2017:160-167. PMC: 5961773. View

19.

Moia R, Patriarca A, Schipani M, Ferri V, Favini C, Sagiraju S . Precision Medicine Management of Chronic Lymphocytic Leukemia. Cancers (Basel). 2020; 12(3). PMC: 7139574. DOI: 10.3390/cancers12030642. View

20.

Hebart H, Lang P, Woessmann W . Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report. Ann Intern Med. 2016; 165(8):607-608. DOI: 10.7326/L16-0037. View